CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Citi’s 2023 18th Annual BioPharma Conference
1x1 Investor Meetings: Thursday, September 7, 2023
Location: Four Seasons Hotel, Boston, MA
H.C. Wainwright 25th Annual Global Investment Conference (Hybrid)
Virtual Presentation: Monday, September 11, 2023
Location: Lotte New York Palace Hotel, New York, NY
Baird’s 2023 Global Healthcare Conference
Presentation: Wednesday, September 13, 2023 at 9:05 am ET
Location: Intercontinental New York Barclay, New York, NY
Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 13, 2023 at 4:15 pm ET
Location: Sheraton Hotel, New York, NY
Live webcasts and archived replays of the presentation at the H.C. Wainwright 25th Annual Global Investment Conference and the fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.24 |
Daily Change: | -0.03 -2.36 |
Daily Volume: | 1,528,702 |
Market Cap: | US$85.150M |
December 27, 2024 September 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB